This device from SwitchBot measures temperature, humidity, carbon dioxide levels and more to keep my home safe during the ...
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies ...
Abbott Diabetes Care has recalled certain glucose monitoring sensors after reports of seven deaths and more than 700 injuries possibly linked to malfunctioning devices that could provide inaccurate ...
Some FreeStyle Libre 3 glucose sensors made by Abbott Diabetes Care may give incorrect low readings. The devices have been ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Designed to provide real-time glucose readings for an ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...
Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback